A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Clinical trial NCT06129864 · RECRUITING
Trial details
- NCT number
- NCT06129864
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-14
- Primary completion
- 2030-04-17
- Enrollment
- 1145
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.